GlassScriptPhysician profile
Ankush Chhabra
NPI 1750308318
$45,643.40
in general payments reported to CMS, 2019-2025
37 companies · $3,826 in 2025
The $3,826 reported for 2025 was more than what 79% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $1,182 · 2021: $1,982 · 2022: $936 · 2023: $1,518 · 2024: $2,670 · 2025: $3,826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,159 · Travel and Lodging: $1,855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,159.02 |
| Travel and Lodging | $1,855.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $20,411.27 | 2019-2023 | Xarelto |
| Edwards Lifesciences Corporation | $17,403.38 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Evoque |
| Medtronic Vascular, INC. | $1,620.58 | 2019-2020 | |
| Medtronic, INC. | $804.39 | 2021-2025 | Micra, Symplicity G3, Corevalve Evolut R |
| Novartis Pharmaceuticals Corporation | $770.97 | 2019-2025 | |
| Abbott Laboratories | $540.83 | 2019-2025 | Mitraclip, Triclip, Navitor |
| Recor Medical INC | $511.18 | 2025 | Paradise Ultrasound Renal Denervation System |
| Abiomed | $397.87 | 2019-2023 | Impella |
| Boston Scientific Corporation | $337.05 | 2019-2025 | Rotapro, Avvigo Guidance System, Watchman Flx |
| Shockwave Medical, INC | $311.95 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $253.46 | 2019-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $253.41 | 2019-2025 | Amvuttra |
| Astrazeneca Pharmaceuticals LP | $216.10 | 2019-2024 | Farxiga, Wainua, Brilinta |
| Philips North America LLC | $200.46 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $175.59 | 2019-2025 | Camzyos, Eliquis |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $160.55 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.54 | 2019-2025 | Jardiance |
| Kiniksa Pharmaceuticals International, Plc | $130.39 | 2024 | Arcalyst |
| Cardiva Medical, INC. | $129.37 | 2023-2024 | Cardiva Vascade 6/7f Vcs, Cardiva Vascade Mvp Vvcs 6-12f, Savvywire |
| Amgen INC. | $126.23 | 2019-2025 | Repatha, Repatha |
| Novo Nordisk INC | $123.93 | 2021-2023 | Ozempic |
| Actelion Pharmaceuticals US, INC. | $73.34 | 2019-2023 | Opsumit, Uptravi |
| Regeneron Healthcare Solutions, INC. | $70.58 | 2019-2022 | |
| Kestra Medical Technology Services, INC. | $63.88 | 2023-2025 | Assure Wcd |
| Irhythm Technologies, INC. | $59.72 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Bayer Healthcare Pharmaceuticals INC. | $59.31 | 2025 | |
| Sanofi-Aventis U.S. LLC | $49.47 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $40.54 | 2023-2025 | Verquvo |
| Kiniksa Pharmaceuticals, LTD. | $39.06 | 2023 | Arcalyst |
| Inspire Medical Systems, INC. | $26.83 | 2025 | Inspire |
| Scpharmaceuticals INC. | $24.01 | 2025 | |
| Cleerly, INC. | $23.02 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Esperion Therapeutics, INC. | $21.21 | 2024 | Nexletol |
| Cook Medical LLC | $19.43 | 2022 | |
| Lilly USA, LLC | $18.78 | 2025 | Mounjaro, Zepbound |
| Genzyme Corporation | $18.58 | 2025 | |
| Electromed, INC. | $17.14 | 2023 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ankush Chhabra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.